Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.63 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14672677 | 0.98 | ADORA2A (0.63) | ADORA2APDE10AKDM4EMAPTMAPK1 | |
| SCHEMBL14672678 | 0.95 | ADORA2A (0.62) | ADORA2APDE10AKDM4EMAPTMAPK1 | |
| SCHEMBL2573914 | 0.80 | ADORA2A (0.62) | ADORA2APDE10AEGLN1 | |
| SCHEMBL2548559 | 0.79 | ADORA2A (0.43) | ADORA2APDE10AEGLN1 | |
| SCHEMBL14672452 | 0.78 | ADORA2A (1.00) | ADORA2APDE10A | |
| SCHEMBL2548172 | 0.75 | ADORA2A (1.00) | ADORA2APDE10A | |
| SCHEMBL2547017 | 0.73 | ADORA2A (0.53) | ADORA2APDE10AKDM4EMAPTMAPK1 | |
| SCHEMBL2556805 | 0.72 | EGLN1 (0.44) | ADORA2APDE10AKDM4EMAPTMAPK1 | |
| SCHEMBL2546203 | 0.72 | ADORA2A (0.60) | ADORA2APDE10AKDM4EMAPTMAPK1 | |
| SCHEMBL14672350 | 0.72 | ADORA2A (1.00) | ADORA2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552909-B1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2A RECEPTOR ANTAGONISTS | PALOBIOFARMA SL (ES) | 2015-03-11 | — | — | EP | disclosed |
| US-8796284-B2 | 4-aminopyrimidine derivatives and their as as adenosine A2a receptor antagonists | PALOBIOFARMA, S.L. (ES) | 2014-08-05 | — | — | US | disclosed |
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | PALOBIOFARMA, S.L. (ES) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053308-A1 | 4-AMINOPYRIMIDINE DERIVATIVES AND THEIR AS AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885PDE10A 506/4885KDM4E 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.